Show simple item record

dc.contributor.authorEstlin, E J
dc.contributor.authorAblett, S
dc.contributor.authorNewell, D R
dc.contributor.authorLewis, I J
dc.contributor.authorLashford, Linda S
dc.contributor.authorPearson, A D
dc.date.accessioned2010-04-07T16:11:41Z
dc.date.available2010-04-07T16:11:41Z
dc.date.issued1996
dc.identifier.citationPhase I trials in paediatric oncology--the European perspective. The New Agents Group of the United Kingdom Childrens Cancer Study Group. 1996, 14 (1):23-32 Invest New Drugsen
dc.identifier.issn0167-6997
dc.identifier.pmid8880390
dc.identifier.doi10.1007/BF00173679
dc.identifier.urihttp://hdl.handle.net/10541/95940
dc.description.abstractThe current recommendations for Phase I trials should allow more confident interpretation of the toxicity and efficacy of new agents by providing a framework for multicentre and international co-operation. An overview of the aims and designs of Phase I trials is presented, along with a summary of current and recently published United Kingdom Childrens Cancer Study Group Phase I trials, and a discussion of some of the difficulties faced in the methodology and evaluation of Phase I studies in children.
dc.language.isoenen
dc.subjectCanceren
dc.subject.meshAntineoplastic Agents
dc.subject.meshChild
dc.subject.meshClinical Trials, Phase I as Topic
dc.subject.meshEurope
dc.subject.meshHumans
dc.subject.meshNeoplasms
dc.titlePhase I trials in paediatric oncology--the European perspective. The New Agents Group of the United Kingdom Childrens Cancer Study Group.en
dc.typeArticleen
dc.contributor.departmentDept. of Child Health, Sir James Spence Institute of Child Health, Royal Victoria Infirmary, Newcastle upon Tyne, UK.en
dc.identifier.journalInvestigational New Drugsen
html.description.abstractThe current recommendations for Phase I trials should allow more confident interpretation of the toxicity and efficacy of new agents by providing a framework for multicentre and international co-operation. An overview of the aims and designs of Phase I trials is presented, along with a summary of current and recently published United Kingdom Childrens Cancer Study Group Phase I trials, and a discussion of some of the difficulties faced in the methodology and evaluation of Phase I studies in children.


This item appears in the following Collection(s)

Show simple item record